<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180204</url>
  </required_header>
  <id_info>
    <org_study_id>2013H000</org_study_id>
    <secondary_id>TALISMAN</secondary_id>
    <nct_id>NCT02180204</nct_id>
  </id_info>
  <brief_title>Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)</brief_title>
  <acronym>TALISMAN</acronym>
  <official_title>Phase IIb Study Comparing Tenecteplase to Alteplase in Acute Ischemic Stroke Within 3 to 4.5 Hours From Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reza Behrouz, DO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of
      intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present
      with symptoms of acute ischemic stroke within 3 to 4.5 hours from onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting with symptoms of acute ischemic stroke (AIS) who present within 3 to 4.5
      hours of symptom onset and who meet the inclusion criteria for intravenous (IV) thrombolysis
      will receive, in a randomized, double-blind fashion, either IV Alteplase at 0.9 mg/kg per
      standard protocol or IV Tenecteplase at 0.25 mg/kg with saline infusion over one hour.
      Patients must also have no exclusion criteria for IV thrombolysis within the 3 to 4.5 hour
      window. The only required imaging is non-contrasted CT of the head. Patients will be
      monitored according to standard post-thrombolytic care. A CT of the head will be performed at
      24 hours based on standard protocol or if there is any neurological change. Neurological
      function at 24 hours using NIHSS and at 3 months based on modified mRS and the NIHSS.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Measured by modified Rankin Scale score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>24 hours</time_frame>
    <description>Twenty-four hour brain CT scan showing intracranial hemorrhage in conjuction with neurological deterioration of 4 points or more on the NIHSS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Tenecteplase 0.25 mg/kg IV - Maximum 25 mg</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>TNKase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Alteplase 0.9 mg/kg IV - Maximum: 90 mg</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Activase</other_name>
    <other_name>t-PA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 80 years

          2. Acute neurologic deficit with an NIHSS ≥ 4

          3. Non-enhanced computed tomography (NECT) of the head showing no hemorrhage

          4. Acute ischemic stroke symptoms with onset, or time last known well, clearly defined
             between 3 and 4.5 hours

          5. Treatment can be initiated within 3 to 4.5 hours from symptom onset

        Exclusion Criteria:

          1. Evidence of intracranial hemorrhage on NECT

          2. Clinical suspicion of subarachnoid hemorrhage even with normal NECT

          3. NECT shows hypo-density greater than 1/3 cerebral hemisphere)

          4. History of intracranial hemorrhage/stroke

          5. Uncontrolled HTN: At time treatment begins SBP remains &gt;185 mmHg or DBP remains &gt;110
             mmHg despite repeated measurements

          6. Known arteriovenous malformation, neoplasm, or aneurysm

          7. Witnessed seizure at stroke onset

          8. Acute bleeding tendencies

          9. Platelet count &lt;100,000/mm3

         10. Heparin received in prior 48 hours with elevated aPTT

         11. Current use of an anticoagulant (Coumadin/Warfarin) irrespective of INR

         12. Prior use (within 48 hours) of direct thrombin inhibitors (dabigatran) or direct
             factor Xa inhibitors (rivaroxaban, apixaban)

         13. Within prior 3 months: intracranial or spinal surgery, head trauma, or previous stroke

         14. Arterial puncture at non-compressible site within last 7 days

         15. Woman of child bearing age who has a positive pregnancy test

         16. NIH stroke scale &gt;25 (severe deficit) or &lt;4 and no dysphasia (mild deficit) or rapidly
             improving

         17. Symptoms spontaneously clearing

         18. 14 days post-operative or post major trauma

         19. Recent gastrointestinal or urinary tract hemorrhage within the past 21 days

         20. Recent acute MI within the past 3 months

         21. Serum glucose &lt;50 mg/dl or &gt;400 mg/dL

         22. Age &gt;80 or less than 18

         23. History of ischemic stroke AND diabetes mellitus

         24. Unable to obtain consent from patient or power of attorney

         25. Baseline mRS &gt; 2

         26. Consent not obtained by 20 minutes prior to closure of the therapeutic window.

         27. The subject has been treated with a thrombolytic agent within the past 72 hours

         28. The subject is a pregnant woman (positive serum βHCG pregnancy test, positive urine
             pregnancy test or clinically evident pregnancy)

         29. The subject is, in the opinion of the investigator, unlikely to comply with the
             clinical study protocol or is unsuitable for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Behrouz, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.</citation>
    <PMID>22435369</PMID>
  </reference>
  <reference>
    <citation>Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, Levi CR. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009 Mar 10;72(10):915-21. doi: 10.1212/01.wnl.0000344168.05315.9d.</citation>
    <PMID>19273826</PMID>
  </reference>
  <reference>
    <citation>Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010 Apr;41(4):707-11. doi: 10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25.</citation>
    <PMID>20185783</PMID>
  </reference>
  <reference>
    <citation>Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005 Mar;36(3):607-12. Epub 2005 Feb 3.</citation>
    <PMID>15692126</PMID>
  </reference>
  <reference>
    <citation>Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6.</citation>
    <PMID>20472172</PMID>
  </reference>
  <reference>
    <citation>Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol. 2014 Jun;261(6):1069-72. doi: 10.1007/s00415-013-7102-0. Epub 2013 Sep 15. Review.</citation>
    <PMID>24036924</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Reza Behrouz, DO</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

